The U.S. Food and Drug Administration (FDA) has approved Bravecto Quantum, a new extended-release injectable suspension that offers dogs and puppies six months of age and older long-lasting protection against fleas and ticks. This is the first FDA-approved medication to provide up to 12 months of continuous protection with a single dose. Bravecto Quantum kills adult fleas and is approved for the treatment and prevention of flea infestations caused by Ctenocephalides felis. It also indicated to treat and control tick infestations caused by Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick) for 12 months. In addition, it treats and controls Amblyomma americanum (lone star tick) infestations for eight months. The product is prescription-only and must be administered by a licensed veterinarian. A veterinarian’s expertise is essential for proper injection, monitoring for potential adverse effects, determining whether the product is appropriate for breeding dogs, and selecting the correct treatment interval based on the tick species the dog may encounter. The active ingredient, fluralaner, is part of the isoxazoline class of antiparasitic drugs, which are widely used in veterinary medicine. While generally safe, FDA reports isoxazoline products have been associated with rare neurological side effects such as tremors, ataxia, or seizures in some animals. For more information, check out the Freedom of Information (FOI) summary.
